Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (14832)	12/20/2004 5:48:07 PM
From: Icebrg	Read Replies (1) \| Respond to of 52153

>>Didn't they contribute a drug to an Alxn collaboration that failed? (Sitaxathan or something similar).>> The partner was Icos, who gave it back. It didn't fail completely, only almost. I believe the drug is still under development. Erik

To: Ian@SI who wrote (14832)	12/20/2004 5:53:37 PM
From: Arthur Radley	Respond to of 52153

Luckily I didn't own this one...only wanted them to be successful as they are local. You are right about the name change...anything with the name Texas in it, you have to be careful. OOPS! That is unless it has DUDE attached. Actually, after reading another release it appears this only applies to a lower dosage they were looking at. However, apparently some side-effects issues have to be addressed, regardless of the dosage amount. What is this with after hours events...I do own CTIC and seems they had a secondary offering that has taken the sails out of the stock in A-H trading.